Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

The purpose of this study is to test the safety of in investigational drug called Liposomal curcumin (LipoCurc) and to find the highest dose that can be given without causing very severe side effects. To do this participants are given LipoCurc and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then new participants will be given a higher dose of LipoCurc. Participants joining this study later on will get higher doses of LipoCurc than participants who join earlier. This will continue until a dose

Trial Details

NCT ID
NCT07456605
Phase
PHASE1
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Liposomal Curcumin (LipoCurc)
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Must be able to understand and voluntarily sign an informed consent form (ICF).
  • Must be ≥ 18 years of age at the time of signing the ICF
  • Must be able to adhere to the study visit schedule and other protocol requirements.
  • Relapsed and/or refractory MM with:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →